T1	Participants 79 107	metastatic colorectal cancer
T2	Participants 225 274	patients with metastatic colorectal cancer (mCRC)
T3	Participants 461 674	17 polymorphisms in genes encoding drug targets, pathway molecules and detoxification enzymes was analyzed in 279 previously untreated mCRC patients treated with capecitabine, oxaliplatin and bevacizumab (CAPOX-B)
T4	Participants 1469 1482	mCRC patients
